Compare IMNM & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMNM | SYRE |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 2020 | 2016 |
| Metric | IMNM | SYRE |
|---|---|---|
| Price | $24.04 | $32.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $31.22 | ★ $56.50 |
| AVG Volume (30 Days) | ★ 2.1M | 569.5K |
| Earning Date | 03-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,679,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.15 | $10.91 |
| 52 Week High | $27.65 | $35.31 |
| Indicator | IMNM | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 57.61 |
| Support Level | $23.86 | $30.92 |
| Resistance Level | $27.65 | $34.07 |
| Average True Range (ATR) | 1.63 | 1.80 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 62.94 | 78.41 |
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.